[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

February 2017 - April 2016

Decade

Year

Issue

November 1, 2016, Vol 1, No. 8, Pages 853-966

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2016;1(8):853. doi:10.1001/jamacardio.2015.0044
Viewpoint

Comparing the SPRINT and the HOPE-3 Blood Pressure Trial

Abstract Full Text
JAMA Cardiol. 2016;1(8):855-856. doi:10.1001/jamacardio.2016.2051

This Viewpoint discusses and compares the outcomes of the SPRINT and the HOPE-3 blood pressure trial.

The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure–Lowering Trials

Abstract Full Text
JAMA Cardiol. 2016;1(8):857-858. doi:10.1001/jamacardio.2016.2169

This Viewpoint compares 5 recent randomized clinical trials of blood pressure lowering involving high- and intermediate-risk participants.

Editorial

Why Cholesterol Testing in Children and Adolescents Matters

Abstract Full Text
JAMA Cardiol. 2016;1(8):859-861. doi:10.1001/jamacardio.2016.2871

This Editorial discusses the US Preventive Services Task Force recommendation statement on screening for lipid disorders in children and adolescents and why this screening is important.

Clinical Outcomes of Patients Who Received the Subcutaneous Implantable Cardioverter Defibrillator

Abstract Full Text
JAMA Cardiol. 2016;1(8):965. doi:10.1001/jamacardio.2016.2877
Original Investigation

Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment

Abstract Full Text
JAMA Cardiol. 2016;1(8):864-871. doi:10.1001/jamacardio.2016.2861

This study uses NHANES data to assess the representativeness of the findings of SPRINT and the HOPE-3 trial to US patients and to explore the cardiovascular disease risk profiles of various populations with elevated systolic blood pressure.

Cost-effectiveness of Intensive Blood Pressure Management

Abstract Full Text
JAMA Cardiol. 2016;1(8):872-879. doi:10.1001/jamacardio.2016.3517

This cost-effectiveness analysis evaluates the incremental cost-effectiveness of intensive blood pressure management compared with standard management in patients with hypertension.

Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac ImagingPredicting Survival for Patients With ATTR Cardiac Amyloidosis

Abstract Full Text
has active quiz
JAMA Cardiol. 2016;1(8):880-889. doi:10.1001/jamacardio.2016.2839

This study describes the diagnostic accuracy of technetium 99m pyrophosphate cardiac imaging for detecting transthyretin cardiac amyloidosis in patient with suspected disease.

Trends and Outcomes of Coronary Angiography and Percutaneous Coronary Intervention After Out-of-Hospital Cardiac Arrest Associated With Ventricular Fibrillation or Pulseless Ventricular Tachycardia

Abstract Full Text
JAMA Cardiol. 2016;1(8):890-899. doi:10.1001/jamacardio.2016.2860

This study uses data from the Nationwide Inpatient Sample to assess the temporal trends, predictors, and outcomes of performing coronary angiography and percutaneous coronary intervention in patients resuscitated after out-of-hospital cardiac arrest with initial rhythms of ventricular tachycardia or pulseless ventricular fibrillation.

Trends and In-Hospital Outcomes Associated With Adoption of the Subcutaneous Implantable Cardioverter Defibrillator in the United States

Abstract Full Text
open access
JAMA Cardiol. 2016;1(8):900-911. doi:10.1001/jamacardio.2016.2782

This cohort study examines the adoption of subcutaneous implantable cardioverter defibrillators (ICDs) into clinical practice in the United States, and compares in-hospital outcomes with those of patients undergoing transvenous ICD implantation.

Clinical Effect of Sex-Specific Cutoff Values of High-Sensitivity Cardiac Troponin T in Suspected Myocardial Infarction

Abstract Full Text
JAMA Cardiol. 2016;1(8):912-920. doi:10.1001/jamacardio.2016.2882

This study (the Advantageous Predictors of Acute Coronary Syndrome Evaluation Study) compares the use of a uniform cutoff level with sex-specific cutoff levels of high-sensitivity coronary troponin T in the diagnosis of acute myocardial infarction.

Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting

Abstract Full Text
JAMA Cardiol. 2016;1(8):921-928. doi:10.1001/jamacardio.2016.3028

This multicenter clinical trial evaluates the safety of preoperative use of ticagrelor with or without aspirin in patients with acute coronary syndromes undergoing isolated coronary artery bypass grafting compared with aspirin alone.

Association Between Depressive Disorders and Incident Acute Myocardial Infarction in Human Immunodeficiency Virus–Infected AdultsVeterans Aging Cohort Study

Abstract Full Text
JAMA Cardiol. 2016;1(8):929-937. doi:10.1001/jamacardio.2016.2716

This cohort study investigates associations between depressive disorders and incident acute myocardial infarction in US veterans with human immunodeficiency virus infection.

Brief Report

Sex and Catheter Ablation for Ventricular TachycardiaAn International Ventricular Tachycardia Ablation Center Collaborative Group Study

Abstract Full Text
JAMA Cardiol. 2016;1(8):938-944. doi:10.1001/jamacardio.2016.2361

This cohort study compares outcomes of women vs men with structural heart disease undergoing ventricular tachycardia ablation.

Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less

Abstract Full Text
JAMA Cardiol. 2016;1(8):945-949. doi:10.1001/jamacardio.2016.2257

This study evaluates patients in the randomized CoreValve US Pivotal High-risk Trial with a Society of Thoracic Surgeons Predictor of Mortality score of 7% or less to determine the benefit of transcatheter aortic valve replacement in lower-risk patients.

Special Communication

The US Food and Drug Administration and the Future of Cardiovascular Medicine

Abstract Full Text
JAMA Cardiol. 2016;1(8):950-952. doi:10.1001/jamacardio.2016.2580

In this Special Communication, FDA Commissioner Robert Califf proposes ways to scale up the national cardiovascular research enterprise through use of interoperable clinical and trial data registries and broadly distributed learning networks.

Review

Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular DiseaseA Review

Abstract Full Text
JAMA Cardiol. 2016;1(8):953-962. doi:10.1001/jamacardio.2016.2750

This review discusses barriers to the clinical implementation of stem cell therapy in patients with cardiovascular disease as well as potential strategies to overcome them.

JAMA Cardiology Clinical Challenge

Spontaneous Cerebral Hemorrhage and Sudden Biventricular Failure After Lung Transplantation

Abstract Full Text
has multimedia
JAMA Cardiol. 2016;1(8):963-964. doi:10.1001/jamacardio.2016.2568

A woman with end-stage lung disease secondary to systemic sclerosis and pulmonary hypertension underwent bilateral sequential lung transplantation without cardiopulmonary bypass through a clamshell thoracotomy and after the operation developed seizures when ambulating. What is your diagnosis?

Comment & Response

Predicting 30-Day Readmission or Death in Patients With Heart FailureLooking Beyond the C Statistic

Abstract Full Text
JAMA Cardiol. 2016;1(8):965. doi:10.1001/jamacardio.2016.3101

Predicting 30-Day Readmission or Death in Heart Failure—ReplyLooking Beyond the C- Statistic

Abstract Full Text
JAMA Cardiol. 2016;1(8):965-966. doi:10.1001/jamacardio.2016.3204
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2016;1(8):854. doi:10.1001/jamacardio.2015.0045
×